Physician profile
Eric Flenaugh
NPI 1689674566
$92,723.81
in general payments reported to CMS, 2019-2025
40 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $8,597 · 2021: $2,875 · 2022: $22K · 2023: $6,429 · 2024: $6,194 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,755 · Consulting Fee: $7,055 · Travel and Lodging: $6,781 · Food and Beverage: $3,790 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,755.00 |
| Consulting Fee | $7,055.00 |
| Travel and Lodging | $6,780.98 |
| Food and Beverage | $3,790.20 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $38,315.07 | 2019-2023 | |
| Olympus America INC. | $19,685.26 | 2021-2025 | Eves Eus Ultrasound Bronchofibervideoscope, Spiration Valve System |
| Cook Medical LLC | $6,524.12 | 2019-2022 | |
| Olympus Medical Systems Corporation | $4,380.00 | 2024 | |
| Cook Incorporated | $4,050.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $2,671.49 | 2023-2025 | Fasenra, Tezspire |
| Medtronic, INC. | $2,409.86 | 2023-2025 | Illumisite |
| Pinnacle Biologics, INC | $2,056.21 | 2022-2025 | Photofrin |
| Intuitive Surgical, INC. | $1,962.03 | 2021-2023 | Da Vinci Surgical System |
| Janssen Pharmaceuticals, INC | $1,535.85 | 2019-2024 | Xarelto |
| Olympus Corporation | $1,468.44 | 2023 | |
| Noah Medical Corporation | $1,187.46 | 2023 | |
| Olympus Corporation of The Americas | $1,186.17 | 2022 | |
| Amgen INC. | $981.25 | 2022-2024 | Lumakras |
| Pfizer INC. | $927.67 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucent Medical | $450.00 | 2025 | |
| Abbvie INC. | $402.81 | 2021-2025 | |
| Gyrus Acmi, INC. | $365.00 | 2023 | |
| Ethicon INC. | $336.60 | 2023-2025 | Monarch Platform |
| Tempus Ai, INC | $236.50 | 2024-2025 | Xt Cdx |
| Actelion Pharmaceuticals US, INC. | $174.03 | 2021-2025 | Opsumit, Uptravi |
| Vapotherm INC | $154.59 | 2021 | |
| Allergan, INC. | $134.64 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $132.74 | 2023-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $123.50 | 2025 | |
| United Therapeutics Corporation | $122.45 | 2025 | |
| Janssen Biotech, INC. | $120.39 | 2025 | Tremfya, Erleada, Rybrevant |
| Inspire Medical Systems, INC. | $115.79 | 2024-2025 | Inspire |
| Boston Scientific Corporation | $92.76 | 2021 | |
| Merck Sharp & Dohme LLC | $89.94 | 2024-2025 | Keytruda, Winrevair, Welireg |
| Insmed, INC. | $77.20 | 2025 | Arikayce |
| Shionogi INC | $60.41 | 2022 | |
| Melinta Therapeutics, LLC | $49.92 | 2022-2024 | Rezzayo, Kimyrsa |
| Vertex Pharmaceuticals Incorporated | $25.06 | 2024 | |
| Glaxosmithkline, LLC. | $24.58 | 2019 | |
| Daiichi Sankyo INC. | $24.33 | 2025 | Enhertu |
| Pulmonx Corporation | $20.12 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Electromed, INC. | $18.23 | 2019 | |
| Medical Device Business Services, INC. | $17.75 | 2025 | Monarch |
| Ambu INC. | $13.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Flenaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.